Mineralys Therapeutics, Inc. (MLYS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
150 N. Radnor Chester Rd.
Radnor, PA 19087
United States of America (the)
Phone
888-378-6240
Website
Sector
Healthcare
Industry
Biotechnology
Employees
51
First IPO Date
February 10, 2023
| Name | Title | Pay | Year Born |
| Jon Congleton | President, Chief Executive Officer & Director | 1.11M | 1963 |
| Brian Taylor Slingsby | Founder & Executive Director | 78,000 | 1977 |
| Adam Scott Levy | Chief Financial Officer & Secretary | 880,190 | 1978 |
| David Rodman | Chief Medical Officer | 881,798 | 1955 |
| Danielle Mahoney | Senior Vice President of Quality Assurance | 0 | N/A |
| Michael Tortorici | Senior Vice President of Translational Medicine | 0 | N/A |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs | 0 | N/A |
| Eric J. Warren | Chief Commercial Officer | 0 | 1972 |
| Jeffrey A. Munsie | Chief Legal Officer | 0 | 1977 |
| Robert McKean | Senior Vice President of CMC | 0 | N/A |
| Jessica Ibbitson | Executive Vice President of Operations | 0 | N/A |
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.